$0.07
(Market cap
$3,816 Mln
Revenue (TTM)
$117 Mln
P/E Ratio
--
P/B Ratio
8.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
4
-
Debt to Equity
0.2
-
Book Value
$--
-
EPS
$-3.9
-
Face value
--
-
Shares outstanding
125,773,162
8 Years Aggregate
CFO
$-167.46 Mln
EBITDA
$-833.86 Mln
Net Profit
$-834.25 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arcus Biosciences (RCUS)
| 22.9 | 3.6 | 15.5 | 176.5 | 13.4 | -0.3 | -- |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Arcus Biosciences (RCUS)
| 60.0 | -21.9 | -7.6 | -48.9 | 55.9 | 157.0 | -6.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arcus Biosciences (RCUS)
|
29.3 | 3,816.0 | 117.0 | -452.0 | -366.7 | -82.6 | -- | 8.1 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 263.0 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Arcus Biosciences (RCUS)
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney... cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California. Read more
-
Co-Founder, Chairman & CEO
Dr. Terry J. Rosen Ph.D.
-
Co-Founder, Chairman & CEO
Dr. Terry J. Rosen Ph.D.
-
Headquarters
Hayward, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Arcus Biosciences (RCUS)
What is the current share price of Arcus Biosciences Inc (RCUS) Today?
The share price of Arcus Biosciences Inc (RCUS) is $29.28 (NYSE) as of 31-Aug-2026 16:05 EDT. Arcus Biosciences Inc (RCUS) has given a return of 13.38% in the last 3 years.
What is the current PB & PE ratio of Arcus Biosciences Inc (RCUS)?
Since, TTM earnings of Arcus Biosciences Inc (RCUS) is negative, P/E ratio is not available.
The P/B ratio of Arcus Biosciences Inc (RCUS) is 8.10 times as on 21-Aug-2026, a 56 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-7.25 |
4.06 |
2024 |
-4.82 |
2.82 |
2023 |
-4.67 |
3.10 |
2022 |
-5.62 |
2.29 |
2021 |
57.54 |
3.62 |
What is the 52 Week High and Low of Arcus Biosciences Inc (RCUS)?
The 52-week high and low of Arcus Biosciences Inc (RCUS) are Rs 31.74 and Rs 10.56 as of 01-Sep-2026.
What is the market cap of Arcus Biosciences Inc (RCUS)?
Arcus Biosciences Inc (RCUS) has a market capitalisation of $ 3,816 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Arcus Biosciences Inc (RCUS)?
Before investing in Arcus Biosciences Inc (RCUS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.